Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Aldred KJ, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N (2013) Nucleic Acids Res 41: 4628-39 Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL, Othus M, Sosman JA, Kirkwood JM, Sondak VK (2012) Clin Cancer Res 18: 1129-37 DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, Shyr Y, Estrada L, Quaranta V, Massion PP (2010) Oncogene 29: 6331-42 A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (2009) J Neurosci 29: 14271-86 Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. Hulgan T, Rosenbloom ST, Hargrove F, Talbert DA, Arbogast PG, Bansal P, Miller RA, Kernodle DS (2004) J Intern Med 256: 349-57 Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. Tian J, Teuscher KB, Aho ER, Alvarado JR, Mills JJ, Meyers KM, Gogliotti RD, Han C, Macdonald JD, Sai J, Shaw JG, Sensintaffar JL, Zhao B, Rietz TA, Thomas LR, Payne WG, Moore WJ, Stott GM, Kondo J, Inoue M, Coffey RJ, Tansey WP, Stauffer SR, Lee T, Fesik SW (2020) J Med Chem 63: 656-675 Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. Felts AS, Rodriguez AL, Smith KA, Engers JL, Morrison RD, Byers FW, Blobaum AL, Locuson CW, Chang S, Venable DF, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Emmitte KA (2015) J Med Chem 58: 9027-40 Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. Aldred KJ, Schwanz HA, Li G, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N (2013) ACS Chem Biol 8: 2660-8 Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. Elsea SH, Osheroff N, Nitiss JL (1992) J Biol Chem 267: 13150-3 Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) J Biol Chem 274: 35927-32 Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N (1991) J Biol Chem 266: 14585-92 A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. Hsiung Y, Elsea SH, Osheroff N, Nitiss JL (1995) J Biol Chem 270: 20359-64 A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. Elsea SH, Hsiung Y, Nitiss JL, Osheroff N (1995) J Biol Chem 270: 1913-20 Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. Corbett AH, Hong D, Osheroff N (1993) J Biol Chem 268: 14394-8 A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential. Corbett AH, Guerry P, Pflieger P, Osheroff N (1993) Antimicrob Agents Chemother 37: 2599-605 Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N (1992) Antimicrob Agents Chemother 36: 751-6 Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme. Froelich-Ammon SJ, McGuirk PR, Gootz TD, Jefson MR, Osheroff N (1993) Antimicrob Agents Chemother 37: 646-51 Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N (1993) Antimicrob Agents Chemother 37: 2179-86 Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice. Gould RW, Dencker D, Grannan M, Bubser M, Zhan X, Wess J, Xiang Z, Locuson C, Lindsley CW, Conn PJ, Jones CK (2015) ACS Chem Neurosci 6: 1683-95 NMR structure of the (+)-CPI-indole/d(GACTAATTGAC)-d(GTCAATTAGTC) covalent complex. Bassarello C, Cimino P, Bifulco G, Boger DL, Smith JA, Chazin WJ, Gomez-Paloma L (2003) Chembiochem 4: 1188-93 Fluorescent detection of Zn(2+)-rich vesicles with Zinquin: mechanism of action in lipid environments. Snitsarev V, Budde T, Stricker TP, Cox JM, Krupa DJ, Geng L, Kay AR (2001) Biophys J 80: 1538-46 Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N (1997) Biochemistry 36: 2919-24 Mechanism of quinolone action and resistance. Aldred KJ, Kerns RJ, Osheroff N (2014) Biochemistry 53: 1565-74 Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Robinson MJ, Corbett AH, Osheroff N (1993) Biochemistry 32: 3638-43 Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL, Osheroff N (2012) Biochemistry 51: 370-81 Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Anderson VE, Osheroff N (2001) Curr Pharm Des 7: 337-53 Molecular imaging of human tumor cells that naturally overexpress type 2 cannabinoid receptors using a quinolone-based near-infrared fluorescent probe. Wu Z, Shao P, Zhang S, Ling X, Bai M (2014) J Biomed Opt 19: 76016 Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes. Osheroff N, Corbett AH, Elsea SH, Westergaard M (1994) Cancer Chemother Pharmacol 34 Suppl: S19-25 Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ (2017) Ann Pharmacother 51: 1008-1022 Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Han C, Chatterjee A, Noetzel MJ, Panarese JD, Smith E, Chase P, Hodder P, Niswender C, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25: 384-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.